Literature DB >> 28249169

miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling.

Rita El Helou1, Guillaume Pinna2, Olivier Cabaud1, Julien Wicinski1, Ricky Bhajun3, Laurent Guyon3, Claire Rioualen4, Pascal Finetti1, Abigaelle Gros1, Bernard Mari5, Pascal Barbry5, Francois Bertucci1, Ghislain Bidaut4, Annick Harel-Bellan2, Daniel Birnbaum1, Emmanuelle Charafe-Jauffret1, Christophe Ginestier6.   

Abstract

Breast cancer stem cells (bCSCs) have been implicated in tumor progression and therapeutic resistance; however, the molecular mechanisms that define this state are unclear. We have performed two microRNA (miRNA) gain- and loss-of-function screens to identify miRNAs that regulate the choice between bCSC self-renewal and differentiation. We find that micro-RNA (miR)-600 silencing results in bCSC expansion, while its overexpression reduces bCSC self-renewal, leading to decreased in vivo tumorigenicity. miR-600 targets stearoyl desaturase 1 (SCD1), an enzyme required to produce active, lipid-modified WNT proteins. In the absence of miR-600, WNT signaling is active and promotes self-renewal, whereas overexpression of miR-600 inhibits the production of active WNT and promotes bCSC differentiation. In a series of 120 breast tumors, we found that a low level of miR-600 is correlated with active WNT signaling and a poor prognosis. These findings highlight a miR-600-centered signaling network that governs bCSC-fate decisions and influences tumor progression.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28249169     DOI: 10.1016/j.celrep.2017.02.016

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  38 in total

1.  MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells.

Authors:  Xuemei Fan; Wei Chen; Ziyi Fu; Lihua Zeng; Yongmei Yin; Hongyan Yuan
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

Review 2.  Metabolic features of cancer stem cells: the emerging role of lipid metabolism.

Authors:  Rita Mancini; Alessia Noto; Maria Elena Pisanu; Claudia De Vitis; Marcello Maugeri-Saccà; Gennaro Ciliberto
Journal:  Oncogene       Date:  2018-02-15       Impact factor: 9.867

Review 3.  Targeting Stearoyl-CoA Desaturase in Solid Tumors.

Authors:  Casie S Kubota; Peter J Espenshade
Journal:  Cancer Res       Date:  2022-05-03       Impact factor: 13.312

4.  Flick the cancer stem cells' switch to turn cancer off.

Authors:  Christophe Ginestier; Daniel Birnbaum; Emmanuelle Charafe-Jauffret
Journal:  Mol Cell Oncol       Date:  2017-04-28

Review 5.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

Review 6.  MicroRNAs, a Promising Target for Breast Cancer Stem Cells.

Authors:  Plabon Kumar Das; Mst Ayesha Siddika; Saharia Yeasmin Asha; Suraiya Aktar; Md Abdur Rakib; Jahan Ara Khanam; Suja Pillai; Farhadul Islam
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

Review 7.  Metabolic signatures of cancer cells and stem cells.

Authors:  Andrew M Intlekofer; Lydia W S Finley
Journal:  Nat Metab       Date:  2019-02-11

Review 8.  Risk Factors and Preventions of Breast Cancer.

Authors:  Yi-Sheng Sun; Zhao Zhao; Zhang-Nv Yang; Fang Xu; Hang-Jing Lu; Zhi-Yong Zhu; Wen Shi; Jianmin Jiang; Ping-Ping Yao; Han-Ping Zhu
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

9.  Inhibition of Stearoyl-CoA Desaturase Induces the Unfolded Protein Response in Pancreatic Tumors and Suppresses Their Growth.

Authors:  Kaitlin Skrypek; Steven Balog; Yoshihiro Eriguchi; Kinji Asahina
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243

10.  Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP.

Authors:  Xuedong Wang; Xinguo Wang; Juan Gu; Ming Zhou; Zhimin He; Xinhui Wang; Soldano Ferrone
Journal:  Oncotarget       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.